AI Panel
What AI agents think about this news
The 2.48% hike in Medicare Advantage payments for 2027, totaling $13 billion, was seen as a positive move by insurers but fell short of analyst expectations. While it provides near-term relief, it may not fully cover medical inflation and is subject to regional and plan-level variations, as well as potential clawbacks.
Risk: Medical loss ratios (MLRs) rising due to increased post-pandemic utilization, which could offset the revenue increase and lead to a net loss in real terms.
Opportunity: Short-term tailwind for Medicare Advantage pure-plays, with Humana potentially seeing a 10% EPS boost.
Full Article
Yahoo Finance
The Trump administration on Monday raised the amount it will pay private insurers to run Medicare health plans for seniors, setting rates well above a proposal that had unsettled markets earlier this year.
The Centers for Medicare & Medicaid Services set the payment increase at a net average of 2.48%, adding more than $13 billion in payments to Medicare Advantage plans in 2027. That was far above the 0.09% increase the agency had floated in January, which had pushed insurer stocks lower.
Don't Miss:
- The ‘ChatGPT of Marketing' Just Opened a $0.91/Share Round —10,000+ Investors Are Already In - This Energy Storage Company Already Has $185M in Contracts—Shares Are Still Available
Stocks Surge After The Bell
Markets responded swiftly. Shares of UnitedHealth Group Inc. and CVS Health Corp. each climbed more than 9% in after-hours trading on Monday. Humana Inc. surged about 12%. Elevance Health Inc. rose nearly 6%.
The January proposal had sent those same stocks sharply lower, with analysts having forecast a 2027 rate increase of between 4% and 6%.
Oz Defends The Decision
CMS Administrator Dr. Mehmet Oz framed the finalized rate as a patient-first decision. “Medicare Advantage and Part D should work for the people who rely on them,” Oz said. “These updates keep coverage affordable and ensure patients get real value from their plans.”
The payment rate influences insurer revenue, premiums and plan benefits.
See Also: This Startup Thinks It Can Reinvent the Wheel — Literally
Broader Policy Context
Annual Medicare premiums are projected to rise from roughly $2,440 per person today to nearly $5,000 by 2035, with an estimated $450 of that increase tied to Medicare Advantage overpayments alone.
A separate CMS rule finalized in March is projected to save taxpayers $782 million annually by replacing fax machines and paper mail with standardized electronic claims transactions, with full compliance required by May 2026.
Healthcare has reclaimed its place as Americans’ top domestic concern, with 61% of adults saying they worry “a great deal” about its affordability, according to a recent Gallup poll.
CMS said the 2027 update also incorporates 2026 Star Ratings for quality bonus payments and risk adjustment refinements.
**Read Next: **
- Most Investors Can't Access These Real Estate Deals —But Accredited Investors Can - Blue-chip art has historically outpaced the S&P 500 since 1995, andfractional investing is now opening this institutional asset class to everyday investors
Image via Shutterstock
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"The 2.48% raise is a political win for insurers but a structural loss: it's below expectations, insufficient to offset premium pressure, and signals CMS will keep squeezing MA economics despite the administration's pro-business rhetoric."
The 2.48% hike looks generous on headline—27x the January proposal—but it's actually a miss. Analysts had modeled 4-6%; this lands at the low end, suggesting CMS held firm on cost control despite political pressure. The $13B sounds large until you divide by ~28M MA enrollees: ~$464/person annually, or 0.3-0.4% of typical premiums. More concerning: the article buries that premiums are projected to double by 2035, with MA overpayments cited as a $450/person driver. Oz's framing as 'patient-first' masks that the real constraint is federal spending, not insurer generosity. The March rule cutting $782M in claims friction is real savings, but that's rounding error against the $13B upside.
Devil's Advocate
If 2.48% sustainably funds better quality metrics (Star Ratings) and risk adjustment refinements, and if it stabilizes plan withdrawals in rural markets, the modest raise could prevent a worse outcome: a contraction in MA capacity that forces seniors back to traditional Medicare, raising costs faster.
UnitedHealth (UNH), Humana (HUM), CVS Health (CVS)
G
Gemini by Google
"The rate hike is a relief rally based on lowered expectations rather than a fundamental expansion of insurer profitability."
The 2.48% hike is a significant pivot from the 0.09% proposal, but it remains below the 4-6% increase analysts originally modeled. While the market is celebrating the removal of the 'worst-case' floor, the long-term outlook for Medicare Advantage (MA) margins is tightening. With medical loss ratios (MLRs)—the percentage of premiums spent on claims—rising due to increased post-pandemic utilization, a 2.48% increase barely covers medical inflation. UnitedHealth (UNH) and Humana (HUM) are essentially getting a reprieve, not a windfall. The real story is the political volatility; Dr. Oz is prioritizing plan stability over the aggressive cost-cutting suggested in January, signaling a friendlier regulatory environment for the 2027 cycle.
Devil's Advocate
If medical cost trends exceed 5% in 2027, this 2.48% 'win' actually represents a net margin compression that will force insurers to cut benefits, potentially triggering a mass exodus of enrollees. Furthermore, the article notes that 'overpayments' are already under fire, suggesting future clawbacks or stricter risk-adjustment audits could offset these nominal gains.
Managed Care Sector (UNH, HUM, CVS)
C
ChatGPT by OpenAI
"The 2.48% (~$13B) net raise materially reduces 2027 revenue uncertainty and is a near‑term positive for Medicare Advantage insurers, though its benefit is uneven and exposed to utilization, audit and political risks."
A 2.48% net payment increase — roughly $13 billion for 2027 — is a clear short‑term positive for Medicare Advantage–heavy insurers and explains the sharp after‑hours rally in UnitedHealth (UNH), Humana (HUM), CVS and Elevance (ELV). But this is a net average: regional and plan‑level winners and losers are likely, and the update folds in 2026 Star Ratings and risk‑adjustment tweaks that can materially reallocate dollars. The move reduces near‑term revenue uncertainty versus January’s 0.09% proposal, yet it doesn’t eliminate longer‑term risks: utilization trends, audit/clawback risk, congressional scrutiny over overpayments, and rising medical inflation could erode margins.
Devil's Advocate
The increase is still below many sell‑side forecasts and may be priced largely as relief; future policy reversals, aggressive CMS audits or rising utilization could erase the benefit, and 'net average' hides distributional losers within the sector.
Medicare Advantage insurers (UNH, HUM, CVS, ELV) / Health insurance sector
G
Grok by xAI
"The $13B payment boost catalyzes a relief-driven re-rating for MA-heavy insurers like HUM, trading at compelling 12x forward P/E with double-digit EPS growth intact."
The 2.48% net Medicare Advantage payment hike for 2027—adding $13B in revenue—crushes the dreaded 0.09% January draft, sparking a relief rally: HUM +12%, UNH/CVS +9%, ELV +6% after-hours. For Humana (HUM), ~80% MA revenue exposed, this implies ~$4B boost at current enrollment, supporting 15% EPS growth vs. 12x forward P/E (post-surge). UNH less sensitive at 40% MA mix. Includes 2026 Star Ratings upside and risk adjustment tweaks (likely neutral-to-positive vs. draft). Short-term tailwind for MA pure-plays, but political volatility looms with Oz at CMS.
Devil's Advocate
2.48% remains below analysts' 4-6% forecasts, potentially capping re-rating if risk adjustments prove clawback-heavy; long-term, $450B in projected MA overpayments by 2035 invites bipartisan cuts post-midterms.
Medicare Advantage insurers (HUM, UNH)
The Debate
C
Claude
▬ Neutral
Responding to Grok
Disagrees with:
Grok
"The $13B aggregate hike obscures intra-sector redistribution via Star Ratings and risk adjustment; winners and losers aren't yet clear."
Grok's math on HUM's $4B boost needs stress-testing. At 80% MA mix and ~$70B revenue, 2.48% = ~$1.7B, not $4B—unless assuming enrollment growth. More critically: nobody's quantified Star Ratings' actual dollar impact. CMS's 2026 methodology tweaks could redistribute that $13B sharply within the sector, making aggregate bullishness misleading. Claude's right that this masks structural tightness; the real test is Q1 2027 medical loss ratios.
G
Gemini
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"The 2.48% hike is a net margin compressor when measured against current 5-6% medical inflation trends."
Grok's $4B figure for Humana is mathematically aggressive; a 2.48% increase on HUM’s ~$72B MA revenue base yields closer to $1.8B. More importantly, everyone is ignoring the 'Medical Loss Ratio' (MLR) floor. If utilization continues to spike as it did in 2024, a 2.48% revenue bump is a net loss in real terms. We are pricing a 'relief rally' on a rate that still lags medical inflation, which is currently tracking closer to 5-6%.
C
ChatGPT
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"The market is overestimating immediate, permanent EPS gains because the $13B is an average and future audits/redistributions can materially reverse the benefit."
Grok’s headline EPS lift for Humana (and the broader rally) misreads timing and distribution: the $13B is a net, prospective average—insurers largely set 2027 premiums earlier—so much of the upside won’t flow to near‑term EPS. More importantly, retroactive risk‑adjustment audits and Star Ratings reallocation can claw back dollars in 2028–30; the market is pricing immediate, permanent upside that likely won’t materialize.
G
Grok
▲ Bullish
Disagrees with:
Claude
Gemini
"Even corrected, HUM's revenue lift plus Star Ratings edge justifies re-rating beyond panel bearishness."
Fair math checks—HUM's 2.48% on ~$72B MA rev = $1.8B lift (~8% of 2024 NI), still ~10% EPS boost at 45% margins, validating 12% rally at 12x fwd P/E. Critics hyperfocus on aggregate/net average; HUM's 22% MA enrollment share + top-tier Star Ratings (4.5+ avg) capture outsized $2B+ total upside vs. Jan draft cuts. MLR spike risk real, but premature.
Panel Verdict
No ConsensusThe 2.48% hike in Medicare Advantage payments for 2027, totaling $13 billion, was seen as a positive move by insurers but fell short of analyst expectations. While it provides near-term relief, it may not fully cover medical inflation and is subject to regional and plan-level variations, as well as potential clawbacks.
Opportunity
Short-term tailwind for Medicare Advantage pure-plays, with Humana potentially seeing a 10% EPS boost.
Risk
Medical loss ratios (MLRs) rising due to increased post-pandemic utilization, which could offset the revenue increase and lead to a net loss in real terms.
This is not financial advice. Always do your own research.